Loading…
Agreement focuses on treatment for Parkinson’s Disease and other neurodegenerative diseases.
Alector, Inc. (Nasdaq: ALEC) announced on October 5, 2026, that it has entered into a global license agreement with Genentech, a member of the Roche Group, for the development and commercialization of AL050, a brain penetrant GCase enzyme replacement therapy. AL050 is designed to address GCase deficiency, a driver of neurodegeneration in Parkinson’s Disease.
Under the terms of the agreement, Alector will receive an upfront payment and is eligible to receive additional development, regulatory, and commercial milestone payments. Alector will also be entitled to tiered royalties on net sales of the product. The agreement grants Genentech exclusive global rights to develop and commercialize AL050.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.